{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:31:29Z","timestamp":1740130289835,"version":"3.37.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Novartis Farma Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Despite the current immunotherapy era, VEGFR inhibitors maintain effectiveness in metastatic renal cell cancer. Real-world data concerning pazopanib are limited. The aim of this study is to add information about efficacy and safety of pazopanib as first-line treatment in metastatic renal cell cancer patients not enrolled into clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective analysis (the PAMERIT study) of first-line pazopanib in real-world metastatic renal cell cancer patients among 39 Centers in Italy. Outcomes were progression-free survival, overall survival, objective response rate and treatment-related adverse events. Kaplan\u2013Meier curves, log-rank test and multivariable Cox\u2019s models were used and adjusted for age, histology, previous renal surgery, International Metastatic RCC Database Consortium score and pazopanib initial dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 474 patients, 87.3% had clear cell metastatic renal cell cancer histology. Most of them (84.6%) had upfront renal surgery. Median progression-free survival and overall survival were 15.8 and 34.4\u00a0months, respectively, significantly correlating with International Metastatic RCC Database Consortium\u2019s good prognosis (P\u00a0&amp;lt;\u00a00.001), ECOG PS 0 (P\u00a0&amp;lt;\u00a00.001), age (&amp;lt;75\u00a0years, P\u00a0=\u00a00.005), surgery (P\u00a0&amp;lt;\u00a00.001) and response to pazopanib (P\u00a0&amp;lt;\u00a00.001). After 3\u00a0months of pazopanib, overall disease control rate have been observed in 76.6% patients. Among International Metastatic RCC Database Consortium\u2019s favorable group patients, 57\/121 (47%) showed complete\/partial response. No unexpected AEs emerged.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this real-world study, metastatic renal cell cancer patients treated with first-line pazopanib reached greater progression-free survival and overall survival than in pivotal studies and had high response rates when belonging to International Metastatic RCC Database Consortium\u2019s favorable group, without new toxicities. Pazopanib has been confirmed a valid first-line option for International Metastatic RCC Database Consortium\u2019s good prognosis metastatic renal cell cancer patients who cannot be submitted to immunotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa193","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T19:15:36Z","timestamp":1601925336000},"page":"484-491","source":"Crossref","is-referenced-by-count":1,"title":["An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the \u2018Pamerit\u2019 study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-8411","authenticated-orcid":false,"given":"Alessandra","family":"Mosca","sequence":"first","affiliation":[{"name":"Medical Oncology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy"},{"name":"Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit 1, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Carten\u00ec","sequence":"additional","affiliation":[{"name":"Division of Oncology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Bersanelli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Naglieri","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Istituto Oncologico Giovanni Paolo II, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[{"name":"Oncology Unit 2, University Hospital of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Boccardo","sequence":"additional","affiliation":[{"name":"Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia, and Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"2021030800224922100_ref1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2021030800224922100_ref2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2021030800224922100_ref3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2021030800224922100_ref4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021030800224922100_ref5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"2021030800224922100_ref6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"2021030800224922100_ref7","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021030800224922100_ref8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdv601","article-title":"Validation of the international metastatic renal-cell carcinoma database consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish oncologic genitourinary group (SOGUG) SPAZO study","volume":"27","author":"P\u00e9rez-Valderrama","year":"2016","journal-title":"Ann Oncol"},{"key":"2021030800224922100_ref9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12894-016-0163-5","article-title":"A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal-cell carcinoma","volume":"16","author":"Kim","year":"2016","journal-title":"BMC Urol"},{"key":"2021030800224922100_ref10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejca.2016.06.016","article-title":"First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium","volume":"65","author":"Ruiz-Morales","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021030800224922100_ref11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1634\/theoncologist.2018-0787","article-title":"Prospective observational study of Pazopanib in patients with advanced renal cell carcinoma (PRINCIPAL study)","volume":"24","author":"Schmidinger","year":"2019","journal-title":"Oncologist"},{"key":"2021030800224922100_ref12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdt492","article-title":"Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials","volume":"25","author":"Heng","year":"2014","journal-title":"Ann Oncol"},{"key":"2021030800224922100_ref13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021030800224922100_ref14"},{"key":"2021030800224922100_ref15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021030800224922100_ref16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000369256","article-title":"Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial","volume":"88","author":"Sternberg","year":"2015","journal-title":"Oncology"},{"key":"2021030800224922100_ref17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021030800224922100_ref18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br J Cancer"},{"key":"2021030800224922100_ref19","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2010.32.9110","article-title":"Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes","volume":"29","author":"Xu","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021030800224922100_ref20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fphar.2017.00329","article-title":"Pazopanib in patients with clear-cell renal cell carcinoma: seeking the right patient","volume":"8","author":"Porta","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021030800224922100_ref21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"2021030800224922100_ref22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"2021030800224922100_ref23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","article-title":"Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium","volume":"66","author":"Heng","year":"2014","journal-title":"Eur Urol"},{"key":"2021030800224922100_ref24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMe1806331","article-title":"Cytoreductive nephrectomy. Patient selection is key","volume":"379","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"2021030800224922100_ref25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.euo.2019.01.005","article-title":"et\u00a0al.","volume":"2","author":"Massari","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"2021030800224922100_ref26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systemic review and meta-analysis of clinical trials in advanced cancer patients","volume":"51","author":"Powles","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021030800224922100_ref27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.euo.2019.02.006","article-title":"Hypertension and cardiovascular morbidity following surgery for kidney cancer","author":"Capitanio","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"2021030800224922100_ref28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.clinthera.2017.01.017","article-title":"Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian National Health Service perspective","volume":"39","author":"Capri","year":"2017","journal-title":"Clin Ther"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/484\/36446186\/hyaa193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/3\/484\/36446186\/hyaa193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:23:13Z","timestamp":1615162993000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/3\/484\/5992404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,20]]},"published-print":{"date-parts":[[2021,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa193","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,11,20]]}}}